Patents Examined by Brian McDowell
  • Patent number: 9975887
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: May 22, 2018
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
  • Patent number: 9975859
    Abstract: Provided is a method for preparing a nitrogen-containing aromatic compound through catalytic pyrolysis from organic materials. The method comprises: feeding organic materials and a catalyst into a reactor, to enable the organic material to undergo reactions in the presence of nitrogen and under heating conditions, so as to generate a reaction system flow containing one or more nitrogen-containing aromatic compounds.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: May 22, 2018
    Assignee: University of Science and Technology of China
    Inventors: Ying Zhang, Lujiang Xu, Qian Yao
  • Patent number: 9963434
    Abstract: Compounds of the Formula wherein A, B, C, D, X, Y, Z, R1, R2, R2?, R3 and n are described herein, selectively negatively modulate NMDA receptors containing an NR2A subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: May 8, 2018
    Assignee: Luc Therapeutics, Inc.
    Inventors: David R Anderson, Robert A Volkmann
  • Patent number: 9951060
    Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 24, 2018
    Assignee: Astellas Pharma Inc.
    Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu
  • Patent number: 9938235
    Abstract: The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: April 10, 2018
    Inventors: Yuqiang Wang, Moussa B. H. Youdim, Yewei Sun, Zaizun Zhang, Gaoxiao Zhang, Pei Yu, Peng Yi, Ming Lang, Wei Liu
  • Patent number: 9938256
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and Z? have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 10, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Dieter Hamprecht, Joerg Kley
  • Patent number: 9889131
    Abstract: Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 13, 2018
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Stephen W. Byers, Sivanesan Dakshanamurthy, Jaime M. Guidry Auvil, Milton L. Brown
  • Patent number: 9884845
    Abstract: There are provided compounds of formula (I) as defined in the specification, which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: February 6, 2018
    Assignee: Respivert Limited
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
  • Patent number: 9862685
    Abstract: The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: January 9, 2018
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
  • Patent number: 9855268
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: January 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Michel Calderini, Ansgar Wegener, Oliver Poeschke
  • Patent number: 9840479
    Abstract: The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R—C(?O)—O— moieties (where R is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids. Also provided are compositions including a described lipidoid and an agent (e.g., polynucleotide, small molecule, peptide, or protein). The present disclosure also provides methods, kits, and uses that involve the lipidoids or compositions for delivering an agent to a subject, tissue, or cell and/or for treating and/or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, immunological diseases, gastrointestinal diseases, respiratory diseases, painful conditions, psychiatric disorders, and metabolic disorders.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: December 12, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Owen Shea Fenton, Joseph Robert Dorkin, Daniel Griffith Anderson, Rebecca L. McClellan
  • Patent number: 9843002
    Abstract: A novel organometallic complex having high color purity is provided. The organometallic complex includes a structure which includes iridium and a ligand and is represented by a general formula (G1). The ligand includes a pyrido[2,3-b]indole skeleton and a pyrimidine skeleton bonded to the 3-position of the pyrido[2,3-b]indole skeleton. The 2-position of the pyrido[2,3-b]indole skeleton and the pyrimidine skeleton are each bonded to the iridium. In the general formula (G1), R1 to R9 each independently represent any of hydrogen, a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group having 6 to 13 carbon atoms, and a substituted or unsubstituted heteroaryl group having 3 to 12 carbon atoms.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: December 12, 2017
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Tomoya Yamaguchi, Hideko Inoue, Tatsuyoshi Takahashi
  • Patent number: 9834538
    Abstract: Provided herein are quinazolinone compounds of formula (I), and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Also provided herein are pharmaceutical compositions comprising the compounds, and methods of use thereof.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: December 5, 2017
    Assignee: Celgene Corporation
    Inventors: George W. Muller, Hon-Wah Man
  • Patent number: 9834558
    Abstract: The present invention relates to novel substituted bridged urea compounds of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: December 5, 2017
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian White
  • Patent number: 9834550
    Abstract: The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: December 5, 2017
    Assignee: DONG-A ST CO., LTD.
    Inventors: Myeong-seop Kim, Taesun Park, Taeyoung Yoon, Seung Min Yang, Hae-Sun Kim, Jun Gyu Kim
  • Patent number: 9828393
    Abstract: Silylalkyloxyaryl compounds useful as anti-cancer agents. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of melanoma, colon, neuroblastoma, bladder, breast, lung, pancreatic, melanoma, sarcoma, lymphoma or gastric cancer.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: November 28, 2017
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventors: Lajos Gera, Robert S. Hodges, Peter Hegyes
  • Patent number: 9828375
    Abstract: The invention belongs to the technical field of organic synthetic drugs, and particularly relates to a pyrazolopyrimidine derivative and a preparation method and medical uses thereof. The invention provides a new pyrazolopyrimidine derivative mainly having position 4 substituted, i.e., position substituted by Y in formula I. The pyrazolopyrimidine derivative of the invention has a structural formula I as follows: The invention provides a new pyrazolopyrimidine derivative and a simple, efficient and low-cost preparation method thereof. The pyrazolopyrimidine derivative of the invention has good inhibitory activity for multiple kinases, has inhibitory action on multiple solid tumors, leukemia and autoimmune diseases, provides a new effective choice for preparation of kinase inhibitors, medicines for autoimmune diseases, angiogenesis inhibitors and antitumor drugs, and has good application prospect.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 28, 2017
    Assignee: Guangxi Wuzhou Pharmaceuticals (Group) Co., Ltd.
    Inventors: Shengyong Yang, Yuquan Wei
  • Patent number: 9828374
    Abstract: The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Guido Galley, Roger Norcross, Angelique Patiny-Adam, Philippe Pflieger
  • Patent number: 9822120
    Abstract: The present invention relates to a novel family of protein kinase inhibitors of Formula I: as well as to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 21, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9815813
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik